These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34505024)

  • 1. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Dai L; Jin B; Liu T; Chen J; Li G; Dang J
    EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Chen DL; Li QY; Tan QY
    J Thorac Dis; 2021 Jan; 13(1):220-231. PubMed ID: 33569202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis.
    Li S; Zhang H; Liu T; Chen J; Dang J
    Front Oncol; 2021; 11():702924. PubMed ID: 34249764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Nov; 8(54):93149-93155. PubMed ID: 29190984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
    J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
    Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
    J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
    Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H
    Front Oncol; 2021; 11():627016. PubMed ID: 34513654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
    Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
    Front Oncol; 2021; 11():732214. PubMed ID: 34557415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
    Liu T; Ding S; Dang J; Wang H; Chen J; Li G
    J Thorac Dis; 2019 Jul; 11(7):2899-2912. PubMed ID: 31463119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
    Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
    Yang K; Li J; Bai C; Sun Z; Zhao L
    Front Oncol; 2020; 10():1098. PubMed ID: 32733805
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
    Front Oncol; 2022; 12():968517. PubMed ID: 36439448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.